Petrelintide is Zealand Pharma's long-acting amylin analog, licensed to Roche as part of the Swiss pharma's late entry into the obesity peptide market. The molecule posted ~10.7% mean weight loss with placebo-like tolerability in ZUPREME-1 (Phase 2), and Zealand and Roche formally endorsed advancement to Phase 3 on April 29, 2026 with H2 2026 initiation confirmed.
The Zealand May 7 Q1 print recognized $700M (DKK 4.5B) in collaboration revenue tied to the Phase 3 milestone, drove a Q1 revenue beat at more than 2× analyst consensus, and authorized a DKK 1.3B share buyback. The stock rose 8.4%. The Roche partnership pairs petrelintide with the GLP-1/GIP agonist enicepatide (CT-388) in a fixed-dose Phase 2 combination starting mid-2026. Roche executives have projected $9B in peak annual sales from the combined obesity pipeline, with petrelintide as a lead asset. Amylin biology — slowing gastric emptying, suppressing glucagon, producing satiety — sits alongside Novo's cagrilintide and Lilly's eloralintide as the next layer beyond GLP-1 monotherapy.
Stories here cover trial readouts, partnership economics, and Roche's obesity-pipeline positioning. See #zealand-pharma, #amylin, and #roche.
Roche presented ZUPREME-1 Phase 2 data for petrelintide, the once-weekly long-acting amylin analog licensed from Zealand Pharma, at the Monday June 8 investor event. The pitch hinges on tolerability: published topline showed up to 10.7% weight loss at 42 weeks versus 1.7% placebo, with discontinuation 4.8% vs 4.9% placebo and no vomiting at the maximally effective dose. Medical Daily framed the readout as a non-incretin option for the estimated 30-40% of patients who quit GLP-1s for GI side effects. Petrelintide advances to Phase 3 alongside enicepatide.
Genentech confirmed at its Monday investor event that the planned Phase 2 multi-arm fixed-dose combination of petrelintide (amylin analog) and enicepatide (GLP-1/GIP) starts mid-2026. The setup mirrors Novo's CagriSema and Lilly's Mounjaro-plus-amylin work, with Roche aiming for the same dual-mechanism economics that produced REIMAGINE 2's head-to-head win this week. Roche projected $9 billion in peak annual sales for the combined obesity pipeline at its Q1 print.
Genentech, Roche's US arm, will present detailed Phase 2 ZUPREME-1 data for the amylin analog petrelintide and Phase 2 CT388-103 data for the GLP-1/GIP agonist enicepatide as late-breakers at ADA 2026, with a June 8 virtual investor event. The Roche obesity package combines the two peptides as a planned fixed-dose Phase 2 combination later this year, and the company has projected $9 billion in peak annual sales for the combined pipeline.
Roche will present detailed Phase 2 ZUPREME-1 data for the amylin analog petrelintide as an ADA 2026 late-breaker, with a June 8 investor event. In 493 adults with overweight or obesity (mean BMI 37), once-weekly petrelintide produced up to 10.7% mean weight loss at week 42 versus 1.7% on placebo, with treatment discontinuation of 4.8% versus 4.9% on placebo and no vomiting or GI-related discontinuations at the maximally effective dose. That tolerability is the amylin class's central pitch against the incretins.
Zealand Pharma A/S held its Extraordinary General Meeting at Plesner Advokatpartnerselskab in Copenhagen on May 26, 2026. All proposals presented were approved, with Camilla Sylvest elected to the Board of Directors as recommended by the Nomination Committee. No other shareholder-elected board composition changes were proposed. Zealand's 2026 pipeline anchors on three programs: petrelintide (ZP8396, amylin analog under a $5.3B March 2026 Roche partnership), survodutide (BI 456906, dual GLP-1/glucagon agonist partnered with Boehringer Ingelheim, SYNCHRONIZE-1 obesity Phase 3 readout April 2026 documenting 16.6% weight loss), and the next-generation amylin and glucagon programs. The corporate-governance update is routine; the strategic story remains the SYNCHRONIZE-MASH Phase 3 readout expected late 2026, which positions survodutide as a leading candidate for the dual GLP-1/glucagon agonist class in MASH alongside pemvidutide.
Zealand Pharma reported Q1 2026 revenue of DKK 34M against DKK 8M a year earlier and the DKK 17M analyst consensus — a more-than-2× beat on the recognition of Roche's $700M (DKK 4.5B) milestone payment tied to petrelintide's advancement into Phase 3. The board authorized a share buyback of up to DKK 1.3B. Net operating expenses came in at DKK 573M (below the DKK 679M consensus), and the company reaffirmed petrelintide Phase 3 obesity initiation in H2 2026. Petrelintide is the long-acting amylin analog that posted ~10.7% mean weight loss with placebo-like tolerability in ZUPREME-1; the Roche partnership combines it with the GLP-1/GIP enicepatide (CT-388) in a fixed-dose Phase 2 starting mid-2026. Shares rose 8.4% to DKK 344.
On the April 23 Q1 call and follow-up coverage, Roche clarified that its two Phase 3 enicepatide (CT-388) obesity trials — ENITH 1 and ENITH 2 — were both successfully initiated in Q1, with the dual GLP-1/GIP agonist on track to compete in the next-wave Phase 3 obesity readouts. Phase 2 reported 22.5% placebo-adjusted weight loss for enicepatide. Roche also confirmed the petrelintide+enicepatide fixed-dose combination Phase 2 will dose its first patient around mid-2026, pairing the Zealand-derived amylin analog (placebo-like tolerability, 10.7% mean weight loss in ZUPREME-1 at week 42) with Roche's stronger GLP-1/GIP backbone. Additional Phase 2 readouts for oral GLP-1 CT-996 are guided before year-end 2026.
Zealand Pharma announced April 29 that it and partner Roche have formally endorsed advancing petrelintide — a long-acting amylin analog suitable for once-weekly subcutaneous administration — into Phase 3 trials for chronic weight management, with initiation planned for H2 2026. The Phase 3 program will evaluate petrelintide as monotherapy and in combination with Roche's GLP-1/GIP receptor dual agonist enicepatide (CT-388). The decision follows positive Phase 2 ZUPREME-1 data showing up to 10.7% weight loss with placebo-like tolerability; petrelintide is now positioned as the lead non-GLP-1 obesity asset behind only Novo's CagriSema.
C&EN published a comprehensive April 2026 feature examining whether amylin analogs — Novo's cagrilintide, Lilly's eloralintide, and Roche/Zealand's petrelintide — can carve meaningful share in a market dominated by semaglutide and tirzepatide. Wall Street initially expected amylin candidates to differentiate on muscle preservation and reduced GI side effects, but as Phase 2 readouts arrive investor enthusiasm has cooled. CagriSema Phase 3 head-to-head against tirzepatide is the make-or-break readout for Novo Nordisk's amylin strategy.
Roche reported Q1 2026 sales up 6% at constant exchange rates and used the earnings call to re-anchor its obesity strategy. Executives project $9 billion in peak annual sales from the emerging breast cancer pill plus four obesity candidates. Lead asset petrelintide (licensed from Zealand Pharma, ZUPREME-1 Phase 2 showed up to 10.7% weight loss with placebo-like tolerability) is positioned at a differentiated patient segment. CEO Schinecker said Roche is not investing in the first generation of obesity drugs, but the next — with petrelintide and CT-388 (enicepatide) data headed for ADA 2026.